ArticleJournal of virology1998
Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma.
Article in Journal of virology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Balance between Retroviral Latency and Transcription: Based on HIV Model.Pathogens (Basel, Switzerland) · 2020Review
- Regulation of Expression and Latency in BLV and HTLV.Viruses · 2020Review
- Epithelial stem cells as mucosal antigen-delivering cells: A novel AIDS vaccine approach.Vaccine · 2015Article
- Tumor-specific suicide gene therapy for hepatocellular carcinoma by transcriptionally targeted retroviral replicating vectors.Gene therapy · 2015Article
- Promoters with cancer cell-specific activity for melanoma gene therapy.Acta naturae · 2011Article
- Tumor-selective gene expression in a hepatic metastasis model after locoregional delivery of a replication-competent retrovirus vector.Clinical cancer research : an official journal of the American Association for Cancer Research · 2006Article
- The perforin-dependent immunological synapse allows T-cell activation-dependent tumor targeting by MLV vector particles.Gene therapy · 2006Article
- Tissue- and tumor-specific targeting of murine leukemia virus-based replication-competent retroviral vectors.Journal of virology · 2006Article
- Plasmid engineering for controlled and sustained gene expression for nonviral gene therapy.Pharmaceutical research · 2006Review
- Inhibition of histone deacetylation in 293GPG packaging cell line improves the production of self-inactivating MLV-derived retroviral vectors.Virology journal · 2006Article
- Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers.Cancer gene therapy · 2005Article
- Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells.Cancer gene therapy · 2005Article
- A simple method to cure established tumors by inflammatory killing of normal cells.Nature biotechnology · 2004Article
- Retroviral hybrid LTR vector strategy: functional analysis of LTR elements and generation of endothelial cell specificity.Gene therapy · 2004Article
- Multiple modifications allow high-titer production of retroviral vectors carrying heterologous regulatory elements.Journal of virology · 2004Article
- A novel attenuated replication-competent adenovirus for melanoma therapy.Gene therapy · 2003Article
- Replicative retroviral vectors for cancer gene therapy.Cancer gene therapy · 2003Article
- Transcriptional Targeting in Cancer Gene Therapy.Journal of biomedicine & biotechnology · 2003Article
- Tissue-specific transcriptional targeting of a replication-competent retroviral vector.Journal of virology · 2002Article
- Durable and stratum-specific gene expression in epidermis.Gene therapy · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To generate transcriptionally targeted vectors, tissue-specific elements of the human tyrosinase promoter were exchanged with corresponding viral elements in the Moloney murine leukemia virus long terminal repeat (LTR). From these experiments, a vesicular stomatitis virus type G pseudotyped, hybrid LTR vector that contained three tyrosinase enhancer elements and gave high-level, tightly tissue-specific expression at high titers (3 x 10(7) CFU/ml) was constructed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.